Guardant Health Inc
Company Profile
Business description
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Contact
3100 Hanover Street
Palo AltoCA94304
USAT: +1 855 698-8887
E: investors@guardanthealth.com
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
2,021
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,586.70 | 15.30 | 0.18% |
| CAC 40 | 7,734.40 | 130.04 | -1.65% |
| DAX 40 | 23,629.58 | 369.59 | -1.54% |
| Dow JONES (US) | 41,603.07 | 256.02 | -0.61% |
| FTSE 100 | 8,717.97 | 21.29 | -0.24% |
| HKSE | 23,601.26 | 56.95 | 0.24% |
| NASDAQ | 18,737.21 | 188.53 | -1.00% |
| Nikkei 225 | 37,160.47 | 174.60 | 0.47% |
| NZX 50 Index | 12,596.50 | 65.75 | -0.52% |
| S&P 500 | 5,802.82 | 39.19 | -0.67% |
| S&P/ASX 200 | 8,360.90 | 12.20 | 0.15% |
| SSE Composite Index | 3,348.37 | 31.82 | -0.94% |